Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome

M. M. Patnaik, E. A. Wassie, E. Padron, F. Onida, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke, C. A. Hanson, R. P. Ketterling, R. Komrokji, A. Tefferi, E. Solary

Research output: Contribution to journalArticle

Abstract

In patients with chronic myelomonocytic leukemia (CMML), age >65 years is an adverse prognostic factor. Our objective in the current study was to examine risk factors for survival and treatment outcome in 261 'young' adults with CMML, as defined by age

Original languageEnglish
Pages (from-to)e270
JournalBlood Cancer Journal
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome'. Together they form a unique fingerprint.

  • Cite this

    Patnaik, M. M., Wassie, E. A., Padron, E., Onida, F., Itzykson, R., Lasho, T. L., Kosmider, O., Finke, C. M., Hanson, C. A., Ketterling, R. P., Komrokji, R., Tefferi, A., & Solary, E. (2015). Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 5(1), e270. https://doi.org/10.1038/bcj.2014.90